| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,000 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$50,778 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stuart Iain |
Chief Scientific Officer |
• – – |
2023-06-30 |
4 |
D |
$4.10 |
$619 |
D/D |
(151) |
10,239 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
D |
$4.10 |
$373 |
D/D |
(91) |
8,017 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2023-05-31 |
4 |
A |
$3.46 |
$12,664 |
D/D |
3,664 |
25,907 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2023-05-31 |
4 |
A |
$3.46 |
$9,560 |
D/D |
2,766 |
53,414 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2023-03-20 |
4 |
B |
$2.50 |
$25,000 |
D/D |
10,000 |
22,721 |
2.74 |
- |
|
| Lepore Patrick G |
Director |
– • – |
2023-03-20 |
4 |
B |
$2.48 |
$49,680 |
D/D |
20,000 |
23,472 |
2.39 |
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2022-12-31 |
4 |
D |
$0.15 |
$272 |
D/D |
(1,813) |
229,144 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-12-31 |
4 |
D |
$0.15 |
$1,603 |
D/D |
(10,685) |
1,064,290 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2022-12-31 |
4 |
D |
$0.15 |
$258 |
D/D |
(1,720) |
220,252 |
|
- |
|
| Zeronda Tyler |
Chief Financial Officer |
• – – |
2022-12-31 |
4 |
D |
$0.15 |
$53 |
D/D |
(354) |
173,005 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-11-30 |
4 |
A |
$0.20 |
$6,861 |
D/D |
34,705 |
1,074,975 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2022-09-30 |
4 |
D |
$0.22 |
$404 |
D/D |
(1,813) |
230,957 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-09-30 |
4 |
D |
$0.22 |
$2,382 |
D/D |
(10,683) |
1,040,270 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2022-09-30 |
4 |
D |
$0.22 |
$383 |
D/D |
(1,719) |
221,972 |
|
- |
|
| Zeronda Tyler |
CFO |
• – – |
2022-09-30 |
4 |
D |
$0.22 |
$79 |
D/D |
(353) |
173,359 |
|
- |
|
| Zeronda Tyler |
CFO |
• – – |
2022-06-30 |
4 |
D |
$0.39 |
$138 |
D/D |
(354) |
173,712 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2022-06-30 |
4 |
D |
$0.39 |
$669 |
D/D |
(1,719) |
223,691 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2022-06-30 |
4 |
D |
$0.39 |
$705 |
D/D |
(1,813) |
232,770 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-06-30 |
4 |
D |
$0.39 |
$4,156 |
D/D |
(10,683) |
1,050,953 |
|
- |
|
| Zeronda Tyler |
CFO |
• – – |
2022-05-31 |
4 |
A |
$0.35 |
$4,332 |
D/D |
12,510 |
174,066 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-05-31 |
4 |
A |
$0.35 |
$4,116 |
D/D |
11,887 |
1,061,636 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2022-03-31 |
4 |
D |
$0.65 |
$2,360 |
D/D |
(3,630) |
234,583 |
|
- |
|
| Zeronda Tyler |
CFO |
• – – |
2022-03-31 |
4 |
D |
$0.65 |
$502 |
D/D |
(773) |
161,556 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2022-03-31 |
4 |
D |
$0.65 |
$2,255 |
D/D |
(3,469) |
225,410 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2022-03-31 |
4 |
D |
$0.65 |
$15,071 |
D/D |
(23,186) |
1,049,749 |
|
- |
|
165 Records found
|
|
Page 2 of 7 |
|
|
